Biocon Limited
Viridian, an FPI, bought 6,26,000 shares of Biocon Limited for ₹25.04 Cr at ₹400.00 apiece in a block deal. A total of 9.2 crore shares, representing a 5.64% stake in Biocon, were sold by Mylan Inc. in block deals on July 14, 2026, for ₹3,680 crore.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Hong Kong based investment manager focused on equity capital markets across Asia Pacific, covering IPOs, placements, block trades and convertible bonds. The firm was founded in 2024 and runs a small team out of Central. Its Indian activity sits almost entirely in recently listed technology and consumer names, built through block deals rather than open market buying.